Alliance Pharma, the Chippenham-based speciality pharmaceutical company, has negotiated new £55m enlarged bank facilities partly to help it hit the acquisition trail.
The group signed the deal with Lloyds Bank and Royal Bank of Scotland on improved terms. 
The new facilities, which replaced earlier facilities and will be available until June 2018, are made up of a £25m term loan, a £25m revolving credit facility and a £5m working capital facility which will be available to fund acquisitions.
Alliance Pharma has grown since its launch in 1998 through the acquisition and licensing of mature pharmaceutical products. It now has a portfolio of more than 50 products across a range of therapy areas.
Finance director Richard Wright said: “We are delighted to put in place these new facilities from Lloyds and RBS. They deliver an improved maturity profile and reduction in cost while leaving Alliance well placed to fund acquisition opportunities which are anticipated over the coming years.”
The group is quoted on the London Stock Exchange's AIM market.
